Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Quanterix (NASDAQ:QTRX - Free Report) from a hold rating to a sell rating in a report published on Thursday morning.

Several other equities analysts have also commented on the stock. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price objective (down from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Canaccord Genuity Group reduced their price target on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Scotiabank reissued an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Finally, Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Quanterix has a consensus rating of "Hold" and an average price target of $15.60.

Quanterix Stock Up 3.0%

Shares of Quanterix stock traded up $0.15 during midday trading on Thursday, hitting $5.00. The company had a trading volume of 241,864 shares, compared to its average volume of 572,280. The stock has a market cap of $193.99 million, a price-to-earnings ratio of -4.71 and a beta of 1.12. The company has a fifty day simple moving average of $5.60 and a 200 day simple moving average of $8.36. Quanterix has a 12-month low of $4.05 and a 12-month high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million during the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, analysts expect that Quanterix will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Quanterix

Institutional investors have recently bought and sold shares of the business. State of Wyoming acquired a new stake in shares of Quanterix during the 1st quarter worth approximately $47,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Quanterix during the 4th quarter worth approximately $55,000. Tower Research Capital LLC TRC grew its stake in shares of Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Quanterix during the 4th quarter worth approximately $66,000. Finally, Quantbot Technologies LP grew its stake in shares of Quanterix by 245.9% during the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company's stock worth $73,000 after purchasing an additional 8,013 shares during the period. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.